Create your own personalized MyJanssenCarePath account to:

  • Check your insurance coverage
  • Enroll in the Janssen CarePath Savings Program, if eligible
  • Sign up for personal treatment reminders

Resources

Resources

Enrollment

Patient Authorization Form — Allows you to authorize the use of your personal information for Janssen CarePath support programs.

Cost Support

Janssen CarePath Savings Program Overview — Provides information on the Janssen CarePath Savings Program for DARZALEX FASPRO™ and eligibility requirements for enrolling in the program.

Janssen CarePath Savings Program Oncology Patient Assignment of Benefits — Allows you to authorize your provider to receive your Janssen CarePath Savings Program rebate on your medication on your behalf.

Patient Affordability Options for DARZALEX FASPRO™ — Gives information on options that can make your treatment more affordable.

Coverage

Health Insurance Open Enrollment Guide — Even if you keep the same health plan, your benefits can change. This guide can help you review your coverage and make changes if needed during the open enrollment period so you can stay on treatment in the new benefit period.

Medicare Resource Guide — Provides information on sources for cost support that may be available to patients enrolled in Medicare.

Medicare Part D and Coverage Gap Guide — Helps you understand the 4 phases of coverage (Deductible, Initial Coverage, Coverage Gap, and Catastrophic Coverage), and when you will enter the Coverage Gap (formerly known as the Donut Hole).

Medicare Low-Income Subsidy (LIS) Brochure — Offers information about extra help with prescription drug costs that is available to low-income residents of the United States enrolled in Medicare Prescription Drug Plans.

Other Resources

Advocacy Connector — A Janssen-sponsored resource that connects patients and caregivers to national and state-specific advocacy groups that offer resources that may be relevant to your needs.

Johnson & Johnson Patient Assistance Foundation (JJPAF) — An independent, nonprofit organization committed to helping eligible patients without insurance coverage receive prescription products donated by Johnson & Johnson operating companies.

What is DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj)?

DARZALEX FASPRO™ is a prescription medicine used to treat adult patients with multiple myeloma:

  • in combination with the medicines bortezomib, melphalan and prednisone in people with newly diagnosed multiple myeloma who cannot receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant)
  • in combination with the medicines lenalidomide and dexamethasone in people with newly diagnosed multiple myeloma who cannot receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant) and in people whose multiple myeloma has come back or did not respond to treatment, who have received at least one prior medicine to treat multiple myeloma
  • in combination with the medicines bortezomib and dexamethasone in people who have received at least one prior medicine to treat multiple myeloma
  • alone in people who have received at least three prior medicines, including a proteasome inhibitor and an immunomodulatory agent, or did not respond to a proteasome inhibitor and an immunomodulatory agent

It is not known if DARZALEX FASPRO™ is safe and effective in children.

 

IMPORTANT SAFETY INFORMATION For DARZALEX FASPRO

Do not receive DARZALEX FASPRO if you have a history of a severe allergic reaction to daratumumab or any of the ingredients in DARZALEX FASPRO™.

Before you receive DARZALEX FASPRO™, tell your healthcare provider about all of your medical conditions, including if you:

  • have a history of breathing problems
  • have had shingles (herpes zoster)
  • have ever had or might now have a hepatitis B infection as DARZALEX FASPRO™ could cause hepatitis B virus to become active again. Your healthcare provider will check you for signs of this infection before, during and for some time after treatment with DARZALEX FASPRO™. Tell your healthcare provider right away if you get worsening tiredness or yellowing of your skin or white part of your eyes.
  • are pregnant or plan to become pregnant. DARZALEX FASPRO™ may harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with DARZALEX FASPRO™.
    • Females who are able to become pregnant should use an effective method of birth control (contraception) during treatment and for at least 3 months after your final dose of DARZALEX FASPRO™. Talk to your healthcare provider about birth control methods that you can use during this time.
    • Before starting DARZALEX FASPRO™ in combination with lenalidomide and dexamethasone, females and males must agree to the instructions in the lenalidomide REMS program.
      • The lenalidomide REMS has more information about effective methods of birth control, pregnancy testing, and blood donation for females who can become pregnant.
      • For males who have female partners who can become pregnant, there is information in the lenalidomide REMS about sperm donation and how lenalidomide can pass into human semen.
  • are breastfeeding or plan to breastfeed. It is not known if DARZALEX FASPRO™ passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

DARZALEX FASPRO™ may cause serious reactions, including:

  • Serious allergic reactions and other severe injection-related reactions. Serious allergic reactions and reactions due to release of certain substances by your body (systemic) that can lead to death, can happen with DARZALEX FASPRO™. Tell your healthcare provider or get medical help right away if you get any of these symptoms during or after an injection of DARZALEX FASPRO™.
    • shortness of breath or trouble breathing
    • dizziness or lightheadedness (hypotension)
    • cough
    • wheezing
    • heart beating faster than usual
    • low oxygen in the blood (hypoxia)
    • throat tightness
    • runny or stuffy nose
    • headache
    • itching
    • high blood pressure
    • nausea
    • vomiting
    • chills
    • fever
    • chest pain
  • Injection site reactions. Skin reactions at or near the injection site (local), including injection site reactions, can happen with DARZALEX FASPRO™. Symptoms may include itching, swelling, bruising, or redness of the skin. These reactions sometimes happen more than 24 hours after an injection of DARZALEX FASPRO™.
  • Decreases in blood cell counts. DARZALEX FASPRO™ can decrease white blood cell counts, which help fight infections, and blood cells called platelets, which help to clot blood. Your healthcare provider will check your blood cell counts during treatment with DARZALEX FASPRO™. Tell your healthcare provider if you develop fever or have signs of bruising or bleeding.
  • Changes in blood tests. DARZALEX FASPRO™ can affect the results of blood tests to match your blood type. These changes can last for up to 6 months after your final dose of DARZALEX FASPRO™. Your healthcare provider will do blood tests to match your blood type before you start treatment with DARZALEX FASPRO™. Tell all of your healthcare providers that you are being treated with DARZALEX FASPRO™ before receiving blood transfusions.

The most common side effects of DARZALEX FASPRO™ when used alone include cold-like symptoms (upper respiratory infection).

The most common side effects of DARZALEX FASPRO™ used in combination therapy include:

  • tiredness
  • nausea
  • diarrhea
  • shortness of breath
  • trouble sleeping
  • fever
  • cough
  • muscle spasms
  • back pain
  • vomiting
  • cold-like symptoms (upper-respiratory infection)
  • nerve damage causing tingling, numbness or pain
  • constipation
  • lung infection (pneumonia)

These are not all the possible side effects of DARZALEX FASPRO™. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of DARZALEX FASPRO

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your healthcare provider or pharmacist for information about DARZALEX FASPRO™ that is written for health professionals.

Active ingredient: daratumumab and hyaluronidase-fihj
Inactive ingredients: L-histidine, L-histidine hydrochloride monohydrate, L-methionine, polysorbate 20, sorbitol, water for injection

Please click here to see the Product Information.

cp-143282v1